HelixBind, Inc
Revolutionizing care for invasive infections such as sepsis
Revolutionizing care for invasive infections such as sepsis
Helixbind is a biotechnology startup founded in 2012 with the slogan "Revolutionizing care for invasive infections such as sepsis." The company focuses on revolutionizing care for invasive infections, specifically sepsis, by providing faster, more accurate, and more informative microbiology results direct from blood. This novel diagnostic platform aids clinicians in identifying bloodstream infections and developing personalized antimicrobial interventions, potentially improving outcomes, saving lives, and reducing the spread of antimicrobial resistance. The company's last investment of $3.00M grant was received on June 17, 2021, from the National Institutes of Health. With headquarters in the United States, Helixbind's innovative approach to addressing invasive infections through advanced diagnostics holds promise for making a significant impact in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $3.00M | 1 | National Institutes of Health | 17 Jun 2021 |
| Grant | $3.00M | 1 | National Institutes of Health | 10 Jun 2020 |
| Grant | $4.00M | 1 |
|
09 Dec 2019 |
| Grant | $2.00M | 1 |
|
15 Mar 2018 |
| Series A | $3.00M | - | 01 Sep 2017 |
No recent news or press coverage available for HelixBind, Inc.
We care about your data, and we'd love to use cookies make your experience better.
